{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:46:55Z","timestamp":1791859615023,"version":"4.3.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genes Immun"],"DOI":"10.1038\/s41435-026-00413-2","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:31:51Z","timestamp":1790663511000},"page":"572-581","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of gut microbiota composition and microbe\u2013host interactions with response to chemoimmunotherapy in gastric cancer"],"prefix":"10.1038","volume":"27","author":[{"given":"Wei","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangfeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6930-7778","authenticated-orcid":false,"given":"Xiaoyan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"413_CR1","first-page":"7","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"413_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"413_CR3","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/S0140-6736(12)60643-6","volume":"381","author":"A Pennathur","year":"2013","unstructured":"Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381:400\u201312.","journal-title":"Lancet"},{"key":"413_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13045-023-01451-3","volume":"16","author":"WL Guan","year":"2023","unstructured":"Guan WL, He Y, Xu RH. Gastric cancer treatment: recent progress and future perspectives. J Hematol Oncol. 2023;16:57.","journal-title":"J Hematol Oncol"},{"key":"413_CR5","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1200\/JCO.2007.13.9378","volume":"26","author":"SE Al-Batran","year":"2008","unstructured":"Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26:1435\u201342.","journal-title":"J Clin Oncol"},{"key":"413_CR6","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1200\/JCO.2004.01.140","volume":"22","author":"O Bouche","year":"2004","unstructured":"Bouche O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study\u2013FFCD 9803. J Clin Oncol. 2004;22:4319\u201328.","journal-title":"J Clin Oncol"},{"key":"413_CR7","doi-asserted-by":"publisher","first-page":"5660","DOI":"10.1200\/JCO.2005.17.376","volume":"23","author":"JA Ajani","year":"2005","unstructured":"Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabral Filho S, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric or gastroesophageal adenocarcinoma. J Clin Oncol. 2005;23:5660\u20137.","journal-title":"J Clin Oncol"},{"key":"413_CR8","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","volume":"402","author":"YY Janjigian","year":"2023","unstructured":"Janjigian YY, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges JP, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402:2197\u2013208.","journal-title":"Lancet"},{"key":"413_CR9","doi-asserted-by":"publisher","first-page":"e180013","DOI":"10.1001\/jamaoncol.2018.0013","volume":"4","author":"CS Fuchs","year":"2018","unstructured":"Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4:e180013.","journal-title":"JAMA Oncol"},{"key":"413_CR10","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461\u201371.","journal-title":"Lancet"},{"key":"413_CR11","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abn0704","volume":"7","author":"G Mirji","year":"2022","unstructured":"Mirji G, Worth A, Bhat SA, El Sayed M, Kannan T, Goldman AR, et al. The microbiome-derived metabolite TMAO drives immune activation and boosts responses to immune checkpoint blockade in pancreatic cancer. Sci Immunol. 2022;7:eabn0704.","journal-title":"Sci Immunol"},{"key":"413_CR12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359:97\u2013103.","journal-title":"Science"},{"key":"413_CR13","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.cell.2017.07.008","volume":"170","author":"T Yu","year":"2017","unstructured":"Yu T, Guo F, Yu Y, Sun T, Ma D, Han J, et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell. 2017;170:548\u2013563.e16.","journal-title":"Cell"},{"key":"413_CR14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillere R, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91\u201397.","journal-title":"Science"},{"key":"413_CR15","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41586-023-06026-3","volume":"617","author":"JS Park","year":"2023","unstructured":"Park JS, Gazzaniga FS, Wu M, Luthens AK, Gillis J, Zheng W, et al. Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance. Nature. 2023;617:377\u201385.","journal-title":"Nature"},{"key":"413_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1312","volume":"13","author":"Z Han","year":"2023","unstructured":"Han Z, Cheng S, Dai D, Kou Y, Zhang X, Li F, et al. The gut microbiome affects response of treatments in HER2-negative advanced gastric cancer. Clin Transl Med. 2023;13:e1312.","journal-title":"Clin Transl Med"},{"key":"413_CR17","doi-asserted-by":"publisher","first-page":"D795","DOI":"10.1093\/nar\/gkab786","volume":"50","author":"L Cheng","year":"2022","unstructured":"Cheng L, Qi C, Yang H, Lu M, Cai Y, Fu T, et al. gutMGene: a comprehensive database for target genes of gut microbes and microbial metabolites. Nucleic Acids Res. 2022;50:D795\u2013D800.","journal-title":"Nucleic Acids Res"},{"key":"413_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.","journal-title":"Nat Commun"},{"key":"413_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-023-00267-8","volume":"9","author":"X Li","year":"2023","unstructured":"Li X, Meng X, Chen H, Fu X, Wang P, Chen X, et al. Integration of single sample and population analysis for understanding immune evasion mechanisms of lung cancer. NPJ Syst Biol Appl. 2023;9:4.","journal-title":"NPJ Syst Biol Appl"},{"key":"413_CR20","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1109\/JBHI.2021.3093027","volume":"25","author":"X Li","year":"2021","unstructured":"Li X, Lin Y, Meng X, Qiu Y, Hu B. An L(0) regularization method for imaging genetics and whole genome association analysis on Alzheimer\u2019s disease. IEEE J Biomed Health Inform. 2021;25:3677\u201384.","journal-title":"IEEE J Biomed Health Inform"},{"key":"413_CR21","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/s41587-019-0209-9","volume":"37","author":"E Bolyen","year":"2019","unstructured":"Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat Biotechnol. 2019;37:852\u20137.","journal-title":"Nat Biotechnol"},{"key":"413_CR22","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41587-020-0548-6","volume":"38","author":"GM Douglas","year":"2020","unstructured":"Douglas GM, Maffei VJ, Zaneveld JR, Yurgel SN, Brown JR, Taylor CM, et al. PICRUSt2 for prediction of metagenome functions. Nat Biotechnol. 2020;38:685\u20138.","journal-title":"Nat Biotechnol"},{"key":"413_CR23","doi-asserted-by":"crossref","unstructured":"Yang C, Mai J, Cao X, Burberry A, Cominelli F, Zhang L. ggpicrust2: an R package for PICRUSt2 predicted functional profile analysis and visualization. Bioinformatics 2023;39:btad470.","DOI":"10.1093\/bioinformatics\/btad470"},{"key":"413_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-023-01586-y","volume":"11","author":"S Lai","year":"2023","unstructured":"Lai S, Yan Y, Pu Y, Lin S, Qiu JG, Jiang BH, et al. Enterotypes of the human gut mycobiome. Microbiome. 2023;11:179.","journal-title":"Microbiome"},{"key":"413_CR25","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/nature09944","volume":"473","author":"M Arumugam","year":"2011","unstructured":"Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of the human gut microbiome. Nature. 2011;473:174\u201380.","journal-title":"Nature"},{"key":"413_CR26","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/nyas.13660","volume":"1417","author":"D Erturk-Hasdemir","year":"2018","unstructured":"Erturk-Hasdemir D, Kasper DL. Finding a needle in a haystack: Bacteroides fragilis polysaccharide A as the archetypical symbiosis factor. Ann N Y Acad Sci. 2018;1417:116\u201329.","journal-title":"Ann N Y Acad Sci"},{"key":"413_CR27","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5834293","volume":"2022","author":"F He","year":"2022","unstructured":"He F, Wang F, Yang J, Yang S. Explore and analyze the composition and characteristics of intestinal microbiota between gastric cancer patients and healthy people. Evid Based Complement Alternat Med. 2022;2022:5834293.","journal-title":"Evid Based Complement Alternat Med"},{"key":"413_CR28","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/j.chom.2022.07.003","volume":"30","author":"H Lu","year":"2022","unstructured":"Lu H, Xu X, Fu D, Gu Y, Fan R, Yi H, et al. Butyrate-producing Eubacterium rectale suppresses lymphomagenesis by alleviating the TNF-induced TLR4\/MyD88\/NF-kappaB axis. Cell Host Microbe. 2022;30:1139\u20131150.e7.","journal-title":"Cell Host Microbe"},{"key":"413_CR29","first-page":"308","volume":"9","author":"AC Gomes","year":"2018","unstructured":"Gomes AC, Hoffmann C, Mota JF. The human gut microbiota: metabolism and perspective in obesity. Gut Microbes. 2018;9:308\u201325.","journal-title":"Gut Microbes"},{"key":"413_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13099-020-00396-z","volume":"13","author":"Y Wang","year":"2021","unstructured":"Wang Y, Wan X, Wu X, Zhang C, Liu J, Hou S. Eubacterium rectale contributes to colorectal cancer initiation via promoting colitis. Gut Pathog. 2021;13:2.","journal-title":"Gut Pathog"},{"key":"413_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.712312","volume":"12","author":"SMS Islam","year":"2021","unstructured":"Islam SMS, Ryu HM, Sayeed HM, Byun HO, Jung JY, Kim HA, et al. Eubacterium rectale attenuates HSV-1 induced systemic inflammation in mice by inhibiting CD83. Front Immunol. 2021;12:712312.","journal-title":"Front Immunol"},{"key":"413_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtbi.2024.111816","volume":"586","author":"X Li","year":"2024","unstructured":"Li X, Feng X, Zhou J, Luo Y, Chen X, Zhao J, et al. A muti-modal feature fusion method based on deep learning for predicting immunotherapy response. J Theor Biol. 2024;586:111816.","journal-title":"J Theor Biol"},{"key":"413_CR33","doi-asserted-by":"crossref","unstructured":"Gao W, Xiong J, Wu G, Chen Y, Lin X. Butyrate-producing Eubacterium rectale inhibits gastric carcinogenesis and augments the efficacy of immunotherapy. J Transl Med. 2026;24:359.","DOI":"10.1186\/s12967-026-07986-6"},{"key":"413_CR34","doi-asserted-by":"publisher","DOI":"10.34133\/research.0127","volume":"6","author":"N Liu","year":"2023","unstructured":"Liu N, Chen L, Yan M, Tao Q, Wu J, Chen J, et al. Eubacterium rectale improves the efficacy of anti-PD1 immunotherapy in melanoma via L-serine-mediated NK cell activation. Research. 2023;6:0127.","journal-title":"Research"},{"key":"413_CR35","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1016\/j.cell.2024.02.022","volume":"187","author":"D Jia","year":"2024","unstructured":"Jia D, Wang Q, Qi Y, Jiang Y, He J, Lin Y, et al. Microbial metabolite enhances immunotherapy efficacy by modulating T cell stemness in pan-cancer. Cell. 2024;187:1651\u20131665.e21.","journal-title":"Cell"},{"key":"413_CR36","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1136\/gutjnl-2023-329543","volume":"72","author":"W Fong","year":"2023","unstructured":"Fong W, Li Q, Ji F, Liang W, Lau HCH, Kang X, et al. Lactobacillus gallinarum-derived metabolites boost anti-PD1 efficacy in colorectal cancer by inhibiting regulatory T cells through modulating IDO1\/Kyn\/AHR axis. Gut. 2023;72:2272\u201385.","journal-title":"Gut"},{"key":"413_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11493-y","volume":"23","author":"Z Jiang","year":"2023","unstructured":"Jiang Z, Mou Y, Wang H, Li L, Jin T, Wang H, et al. Causal effect between gut microbiota and pancreatic cancer: a two-sample Mendelian randomization study. BMC Cancer. 2023;23:1091.","journal-title":"BMC Cancer"}],"container-title":["Genes & Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41435-026-00413-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41435-026-00413-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41435-026-00413-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:20:38Z","timestamp":1791858038000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41435-026-00413-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":37,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["413"],"URL":"https:\/\/doi.org\/10.1038\/s41435-026-00413-2","relation":{},"ISSN":["1476-5470"],"issn-type":[{"value":"1476-5470","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"18 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}